Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics, Inc. - Common Stock (NQ:SGMO)

0.5856 -0.0121 (-2.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sangamo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
8 Analysts Assess Sangamo Therapeutics: What You Need To Know
 
Via Benzinga
US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'
U.S. stock futures were flat on Tuesday after a bounce back on Monday. Futures of all four benchmark indices were mixed in premarket trading. 
Via Benzinga
IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday
 
Via Benzinga
Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss
Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB. 
Via Stocktwits
Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts
 
Via Benzinga
9 Analysts Have This To Say About Sangamo Therapeutics
 
Via Benzinga
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For March 17, 2025
 
Via Benzinga
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
From Sangamo Therapeutics, Inc.
Via Business Wire
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes
Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi. 
Via Benzinga
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
From Sangamo Therapeutics, Inc.
Via Business Wire
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide
 
Via Benzinga
Topics Stocks
Stocks Lower Midday As 2024 Comes To An End
Stocks are lower midday, as Wall Street heads for its second consecutive winning year. 
Via Talk Markets
Topics Stocks / Equities
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet
 
Via Benzinga
US Stocks Open Higher; House Prices Increase In October
 
Via Benzinga
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results. 
Via Benzinga
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Why Cemtrex Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
US Stocks Poised To Open Higher On Last Trading Day Of 2024: Analyst Sees S&P 500 At 7,000 In First Half Of 2025
U.S. stock futures were trading higher on Tuesday following Monday's selloff. All four index futures rose in trade. 
Via Benzinga
Topics Stocks
CompoSecure, Cemtrex And 3 Stocks To Watch Heading Into Tuesday
U.S. stock futures down, investors eye EHang, Sangamo, Cemtrex, CompoSecure, Ambow. Check out Benzinga's premarket coverage & top tech stocks to watch. 
Via Benzinga
Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec
From Sangamo Therapeutics, Inc.
Via Business Wire
US Stocks Likely To Open Higher After Plunging On Powell's Hawkish Comments: Analyst Calls It A 'Healthy' Reaction From An 'Overly Optimistic' Market
U.S. stock futures climbed on Thursday in premarket hours after a hawkish cut from the Federal Reserve on Wednesday. 
Via Benzinga
Topics Economy
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
From Sangamo Therapeutics, Inc.
Via Business Wire
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.